A UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics.
16-Oct-2017 – 2765p – £142.1m
Preliminary Results For The Year To End June 2017 – Good news all round here –Revenue up 31% to £7.2m and PBT up 37% to £5.7m – A second Interim Dividend of 31p and a Special Dividend of 40p.
Wish I’d paid up here on the breakout above 2000p. The PER of 32.1 seems justified.
Subsequently revised Watchlist price, 2000p.
26-Mar-2018 – 2068p – £106.3m – PER 21.7
Interim Results For The 6 Months To End December 2017 – Revenue up 13%, PBT up 36%, Interim Dividend up 20% and Cash of £5.6m.
Looks reasonable to me with what looks like strong support around the 1900p level, I will put it on my Watchlist, 1950p.
8-Oct-2018 – 3220p – £165.5m – PER 32.2
Results For The 12 Months To End June 2018 – Revenue up 21% to £8.8m, PBT up 19% to £6.9m, Cash up £0.8m to £7m, Second Interim Dividend of 36p (2017: 31p) and a Special Dividend of 55p (2017: 40p).
Another one of my casualties from waiting for pullbacks and not paying up (have now gladly changed this approach)! Remains on my Watchlist.
Subsequent note: Further research suggested a fall in EPS this year so I will go Neutral here for now and keep an eye out for updates.
29-Mar-2019 – 3600p – £185m – PER 29.3
Interim Results For The 6 Months To End December 2018 – Revenue and PBT up 24%, Cash at £5.5m (£5.6m last time), Interim Dividend up 20%.
I keep missing out here always thinking it looks too expensive. I guess I will just sit and watch it go higher as I always consider it too expensive!
21-Oct-2019 – 3560p – £183m – PER 32
Results For The 12 Months To End June 2019 – Revenue up 6%, PBT up 1%, 2nd Interim Dividend of 43p (36p) and a Special Dividend of 47p (55p).
I have been calling this as too expensive since it was about half this price, I still think it’s too expensive but, it always seems to do well, mostly based on future potential of antibody projects.